| Literature DB >> 28670236 |
Akshita Gupta1, Sawan Bopanna1, Saurabh Kedia1, Dawesh Prakash Yadav1, Sandeep Goyal1, Saransh Jain1, Govind Makharia1, Vineet Ahuja1.
Abstract
BACKGROUND/AIMS: Familial occurrence of inflammatory bowel disease (IBD) is well documented. Reports from Western countries have shown a higher familial occurrence of ulcerative colitis (UC) in first- and second-degree relatives than that in the Asian UC population. No data are currently available from the Indian subcontinent in this regard. We present our data on the familial aggregation of UC.Entities:
Keywords: Colitis, ulcerative; Medical history taking
Year: 2017 PMID: 28670236 PMCID: PMC5478764 DOI: 10.5217/ir.2017.15.3.388
Source DB: PubMed Journal: Intest Res ISSN: 1598-9100
Fig. 1Flow chart showing prevalence of family history of IBD in patients with UC.
Comparison of Clinical Features in Sporadic and Familial UC (n=2,058)
| Sporadic UC | Familial UC | ||||
|---|---|---|---|---|---|
| All patients | Patients with 1st-degree relatives affected | Patients with 2nd-degree relatives affected | |||
| No. of patients | 2,027 | 31a | 26 | 7 | |
| Male sex (%) | 65.8 | 38.7 | 42.3 | 28.6 | 0.002 |
| Age at onset (yr) | 32.2±12.1 | 33.0±9.7 | 33.8±9.9 | 31.0±9.5 | 0.400 |
| Age at diagnosis (yr) | 32.5±12.1 | 35.1±10.5 | 35.7±11.4 | 33.6±11.2 | 0.100 |
| Duration of illness (yr) | 5.8±6.6 | 12.4±9.4 | 11.8±9.3 | 14.3±9.4 | <0.001 |
| Age at last follow-up (yr) | 38.3±12.9 | 45.4±14.4 | 45.5±15.0 | 45.3±14.8 | 0.003 |
| Duration of follow-up (yr) | 5.6±6.7 | 10.5±8.6 | 9.9±8.6 | 12.1±8.7 | <0.001 |
| Extent at diagnosis (%) | 0.002 | ||||
| E1 (proctitis) | 14.4 | 37.9 | 37.5 | 28.6 | |
| E2 (left-sided colitis) | 42.4 | 34.5 | 33.3 | 42.8 | |
| E3 (extensive colitis) | 43.2 | 27.6 | 29.2 | 28.6 | |
| EIM+ (%) | 26.8 | 48.3 | 66.7 | 57.1 | 0.010 |
| Surgery (%) | 2.2 | 3.4 | 4.2 | 0 | 0.600 |
| Ever use of medication (%) | |||||
| Mesalamine | 80.7 | 72.4 | 66.7 | 85.7 | 0.300 |
| Other aminosalicylate | 16.6 | 17.2 | 16.7 | 14.3 | 0.900 |
| Sulfasalazine | 11.5 | 6.9 | 4.2 | 14.3 | 0.400 |
| Corticosteroids | 68.6 | 65.5 | 70.8 | 42.9 | 0.700 |
| Azathioprine | 18.9 | 31.1 | 29.2 | 28.6 | 0.100 |
| Infliximab | 0.6 | 0 | 0 | 0 | 0.700 |
| Probiotics | 9.9 | 20.7 | 20.8 | 14.3 | 0.060 |
Values are presented as mean±SD.
aTwo patients had both 1st- and 2nd-degree relatives affected.
EIM, extraintestinal manifestations.
Frequency of IBD among First- and Second-Degree Relatives
| Frequency (%) | |
|---|---|
| 1st-degree relatives | |
| Brother | 9 (30.0) |
| Sister | 7 (23.3) |
| Father | 5 (16.7) |
| Mother | 3 (10.0) |
| Son | 3 (10.0) |
| Daughter | 3 (10.0) |
| 2nd-degree relatives | |
| Grandfather | 1 (12.5) |
| Grandmother | 0 |
| Uncle | 2 (25.0) |
| Aunt | 3 (37.5) |
| Nephew | 1 (12.5) |
| Niece | 1 (12.5) |
Extraintestinal Manifestations in UC Patients and Their Family Members
| EIM | UC patient (n=29) | 1st-degree relative (n=20) |
|---|---|---|
| Frequency (%) | Frequency (%) | |
| Total | 14 (48.3) | 7 (35.0) |
| Peripheral and central arthralgias | 7 (24.1) | 3 (15.0) |
| Aphthous ulcers | 5 (17.2) | 3 (15.0) |
| Psoriasis | 1 (3.5) | 1 (5.0) |
| Pellagra | 1 (3.5) | 0 |
EIM, extraintestinal manifestations.